399 related articles for article (PubMed ID: 19324597)
21. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis.
Vojvodich PF; Hansen JB; Andersson U; Sävendahl L; Hagelberg S
J Rheumatol; 2007 Dec; 34(12):2481-5. PubMed ID: 18050366
[TBL] [Abstract][Full Text] [Related]
22. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis.
Henrickson M; Reiff A
J Rheumatol; 2004 Oct; 31(10):2055-61. PubMed ID: 15468375
[TBL] [Abstract][Full Text] [Related]
23. Etanercept therapy in children with treatment-resistant uveitis.
Reiff A; Takei S; Sadeghi S; Stout A; Shaham B; Bernstein B; Gallagher K; Stout T
Arthritis Rheum; 2001 Jun; 44(6):1411-5. PubMed ID: 11407702
[TBL] [Abstract][Full Text] [Related]
24. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.
Kimura Y; Pinho P; Walco G; Higgins G; Hummell D; Szer I; Henrickson M; Watcher S; Reiff A
J Rheumatol; 2005 May; 32(5):935-42. PubMed ID: 15868633
[TBL] [Abstract][Full Text] [Related]
25. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
van Dijken TD; Vastert SJ; Gerloni VM; Pontikaki I; Linnemann K; Girschick H; Armbrust W; Minden K; Prince FH; Kokke FT; Nieuwenhuis EE; Horneff G; Wulffraat NM
J Rheumatol; 2011 Jul; 38(7):1441-6. PubMed ID: 21459936
[TBL] [Abstract][Full Text] [Related]
26. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis.
Masi L; Ricci L; Zulian F; Del Monte F; Simonini G; Capannini S; De Martino M; Brandi ML; Falcini F
J Rheumatol; 2009 Oct; 36(10):2308-13. PubMed ID: 19684155
[TBL] [Abstract][Full Text] [Related]
27. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
28. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
[TBL] [Abstract][Full Text] [Related]
29. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register.
Prince FH; de Bekker-Grob EW; Twilt M; van Rossum MA; Hoppenreijs EP; ten Cate R; Koopman-Keemink Y; Gorter SL; Raat H; van Suijlekom-Smit LW
Rheumatology (Oxford); 2011 Jun; 50(6):1131-6. PubMed ID: 21278067
[TBL] [Abstract][Full Text] [Related]
30. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
Otten MH; Prince FH; Ten Cate R; van Rossum MA; Twilt M; Hoppenreijs EP; Koopman-Keemink Y; Oranje AP; de Waard-van der Spek FB; Gorter SL; Armbrust W; Dolman KM; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2011 Feb; 70(2):337-40. PubMed ID: 21068101
[TBL] [Abstract][Full Text] [Related]
31. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.
Papsdorf V; Horneff G
Rheumatology (Oxford); 2011 Jan; 50(1):214-21. PubMed ID: 21148155
[TBL] [Abstract][Full Text] [Related]
32. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
Sevcic K; Orban I; Brodszky V; Bazso A; Balogh Z; Poor G; Kiss E
Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001
[TBL] [Abstract][Full Text] [Related]
33. Treatment with etanercept for patients with juvenile rheumatoid arthritis in Taiwan--a preliminary report.
Liang TC; Yang YH; Lin YT; Chiang BL
J Microbiol Immunol Infect; 2005 Dec; 38(6):447-50. PubMed ID: 16341347
[TBL] [Abstract][Full Text] [Related]
34. Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis.
Ringold S; Chon Y; Singer NG
Arthritis Rheum; 2009 Dec; 60(12):3776-83. PubMed ID: 19950286
[TBL] [Abstract][Full Text] [Related]
35. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis.
Prince FH; Twilt M; Simon SC; van Rossum MA; Armbrust W; Hoppenreijs EP; Kamphuis S; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; ten Cate R; van Suijlekom-Smit LW
Ann Rheum Dis; 2009 Jul; 68(7):1228-9. PubMed ID: 19525408
[No Abstract] [Full Text] [Related]
36. Advanced therapy for juvenile arthritis.
Murray KJ; Lovell DJ
Best Pract Res Clin Rheumatol; 2002 Jul; 16(3):361-78. PubMed ID: 12387805
[TBL] [Abstract][Full Text] [Related]
37. Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort.
Oen K; Duffy CM; Tse SM; Ramsey S; Ellsworth J; Chédeville G; Chetaille AL; Saint-Cyr C; Cabral DA; Spiegel LR; Schneider R; Lang B; Huber AM; Dancey P; Silverman E; Rosenberg AM; Cameron B; Johnson N; Dorval J; Scuccimarri R; Campillo S; Petty RE; Duffy KN; Boire G; Haddad E; Houghton K; Laxer R; Turvey SE; Miettunen P; Gross K; Guzman J; Benseler S; Feldman BM; Espinosa V; Yeung RS; Tucker L
Arthritis Care Res (Hoboken); 2010 Apr; 62(4):527-36. PubMed ID: 20391508
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
[TBL] [Abstract][Full Text] [Related]
39. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.
Russo RA; Katsicas MM
J Rheumatol; 2009 May; 36(5):1078-82. PubMed ID: 19435972
[TBL] [Abstract][Full Text] [Related]
40. Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis.
Remesal A; DE Inocencio J; Merino R; Garcia-Consuegra J
J Rheumatol; 2010 Sep; 37(9):1970-1. PubMed ID: 20810527
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
